<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337675</url>
  </required_header>
  <id_info>
    <org_study_id>0476-302</org_study_id>
    <secondary_id>MK0476-302</secondary_id>
    <secondary_id>2006_015</secondary_id>
    <nct_id>NCT00337675</nct_id>
  </id_info>
  <brief_title>Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast (Daily Dosing and Intermittent, Episode-Driven Dosing) Compared With Placebo in the Treatment of Episodic Asthma in Children Aged 6 Months to 5 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a year-long study evaluating the efficacy of both daily and intermittent treatment of
      asthma in children who experience symptoms episodically (i.e., seasonally, usually in the
      context of upper respiratory tract infection).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period</measure>
    <time_frame>1-year treatment period</time_frame>
    <description>The rate per year of asthma episodes culminating in an asthma attack for each of the 3 treatment groups. Asthma attacks were defined as respiratory symptoms requiring healthcare resource utilization (HRU), which comprised unscheduled visits to a physician or emergency department, treatment with corticosteroids (oral, rectal, or inhaled), or hospitalization. Each day during an episode, the patient's legal guardian recorded all the HRU that was required specifically for breathing problems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily Average of Wheeze and Difficulty Breathing in the 3 Days Prior to Start of an Asthma Attack Within an Asthma Episode</measure>
    <time_frame>1 Year</time_frame>
    <description>Each day during an asthma episode, the patient's legal guardian was asked to rate each of the symptoms of wheeze and difficulty breathing on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 3 days prior to an asthma attack was reported. If a patient had multiple episodes during 1 year, the symptom scores were averaged across all the episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Average of the Mean Symptom Scores (Wheeze, Difficulty Breathing, Interference With Activity, and Daytime Cough) Assessed Over the 12-day Treatment Period of Asthma Episodes</measure>
    <time_frame>1 Year</time_frame>
    <description>Each day during an asthma episode, the patient's legal guardian was asked to rate each of the symptoms of Wheeze, Difficulty Breathing, Interference with Activity, and Daytime Cough on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 12 days of intermittent treatment for an episode (before the first attack) was reported. If a patient had multiple episodes over 1 year, the symptom scores were averaged across all the episodes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1771</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Arm 1: drug + episodic supplemental placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Montelukast once a day (qd) + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: placebo comparator + episodic supplemental drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo qd + episode driven supplemental Montelukast qd for 12 days for a 52-wk treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: placebo comparator + episodic supplemental placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo qd + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.</description>
    <arm_group_label>Arm 1: drug + episodic supplemental placebo</arm_group_label>
    <other_name>MK0476</other_name>
    <other_name>Singulair®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo (unspecified)</intervention_name>
    <description>Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.</description>
    <arm_group_label>Arm 3: placebo comparator + episodic supplemental placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast sodium</intervention_name>
    <description>Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.</description>
    <arm_group_label>Arm 2: placebo comparator + episodic supplemental drug</arm_group_label>
    <other_name>MK0476</other_name>
    <other_name>Singulair®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 6 months to 5 years with episodic (periodic) asthma

        Exclusion Criteria:

          -  Patients who are not in otherwise good health

          -  Patients who have persistent asthma (continual asthma symptoms)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <results_reference>
    <citation>Valovirta E, Boza ML, Robertson CF, Verbruggen N, Smugar SS, Nelsen LM, Knorr BA, Reiss TF, Philip G, Gurner DM. Intermittent or daily montelukast versus placebo for episodic asthma in children. Ann Allergy Asthma Immunol. 2011 Jun;106(6):518-26. doi: 10.1016/j.anai.2011.01.017. Epub 2011 Mar 4.</citation>
    <PMID>21624752</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2006</study_first_submitted>
  <study_first_submitted_qc>June 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2006</study_first_posted>
  <results_first_submitted>February 19, 2010</results_first_submitted>
  <results_first_submitted_qc>February 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2010</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 111 centers worldwide.
Patient screening began 16-Oct-2006 and the first patient was randomized on 3-Nov-2006.
The last patient's last visit was completed on 12-Aug-2009.</recruitment_details>
      <pre_assignment_details>1979 screened; 208 excluded.
Randomized patients met the following criteria: age 6-71 months, a history of episodic asthma symptoms that ranged between 2 and 6 episodes, depending on age, that were separated in time by periods without asthma symptoms. Patients had at least 1 corticosteroid treatment or were hospitalized for asthma at least 1 time.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Daily Montelukast</title>
          <description>Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
        <group group_id="P2">
          <title>Intermittent Montelukast</title>
          <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="589"/>
                <participants group_id="P2" count="591"/>
                <participants group_id="P3" count="591"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="492"/>
                <participants group_id="P2" count="488"/>
                <participants group_id="P3" count="492"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daily Montelukast</title>
          <description>Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
        <group group_id="B2">
          <title>Intermittent Montelukast</title>
          <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="589"/>
            <count group_id="B2" value="591"/>
            <count group_id="B3" value="591"/>
            <count group_id="B4" value="1771"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.0" lower_limit="6.0" upper_limit="71.0"/>
                    <measurement group_id="B2" value="39.5" lower_limit="6.0" upper_limit="71.0"/>
                    <measurement group_id="B3" value="39.3" lower_limit="7.0" upper_limit="71.0"/>
                    <measurement group_id="B4" value="39.2" lower_limit="6.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="238"/>
                    <measurement group_id="B4" value="703"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="350"/>
                    <measurement group_id="B2" value="365"/>
                    <measurement group_id="B3" value="353"/>
                    <measurement group_id="B4" value="1068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period</title>
        <description>The rate per year of asthma episodes culminating in an asthma attack for each of the 3 treatment groups. Asthma attacks were defined as respiratory symptoms requiring healthcare resource utilization (HRU), which comprised unscheduled visits to a physician or emergency department, treatment with corticosteroids (oral, rectal, or inhaled), or hospitalization. Each day during an episode, the patient’s legal guardian recorded all the HRU that was required specifically for breathing problems.</description>
        <time_frame>1-year treatment period</time_frame>
        <population>Full Analysis Set (FAS): all randomized patients who took at least one dose of blinded study drug. Of 1771 patients randomized, 5 never took study drug and 9 were not included due to Good Clinical Practice compliance concerns. Therefore, 1757 patients were included in the FAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Montelukast</title>
            <description>Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Montelukast</title>
            <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period</title>
          <description>The rate per year of asthma episodes culminating in an asthma attack for each of the 3 treatment groups. Asthma attacks were defined as respiratory symptoms requiring healthcare resource utilization (HRU), which comprised unscheduled visits to a physician or emergency department, treatment with corticosteroids (oral, rectal, or inhaled), or hospitalization. Each day during an episode, the patient’s legal guardian recorded all the HRU that was required specifically for breathing problems.</description>
          <population>Full Analysis Set (FAS): all randomized patients who took at least one dose of blinded study drug. Of 1771 patients randomized, 5 never took study drug and 9 were not included due to Good Clinical Practice compliance concerns. Therefore, 1757 patients were included in the FAS population.</population>
          <units>Asthma attacks within episodes per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="584"/>
                <count group_id="O2" value="588"/>
                <count group_id="O3" value="585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.86" upper_limit="1.14"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.92" upper_limit="1.22"/>
                    <measurement group_id="O3" value="1.05" lower_limit="0.92" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis stated that montelukast (daily regimen, or [intermittent and daily regimens]), compared with placebo, results in a decrease in the number of asthma episodes culminating in asthma attack in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year. A sample size of 450 evaluable patients per arm allowed the detection of a difference in rate of 23% with 90% power.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.510</p_value>
            <p_value_desc>Multiplicity adjustment across regimens was addressed through step-down testing. Daily montelukast versus placebo was tested first; if this comparison was significant, intermittent montelukast versus placebo was tested. The significance level was 5%.</p_value_desc>
            <method>Regression, Poisson</method>
            <method_desc>A Poisson regression model containing factors for treatment, age group, and geographic region, and an offset for number of days in study was used.</method_desc>
            <param_type>Rate reduction</param_type>
            <param_value>5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>19.6</ci_upper_limit>
            <estimate_desc>Rate reduction = (1 - montelukast-adjusted annual rate/placebo-adjusted annual rate) x 100%</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary hypothesis stated that montelukast (daily regimen, or [intermittent and daily regimens]), compared with placebo, results in a decrease in the number of asthma episodes culminating in asthma attack in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year. A sample size of 450 evaluable patients per arm allowed the detection of a difference in rate of 23% with 90% power.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.884</p_value>
            <p_value_desc>Multiplicity adjustment across regimens was addressed through step-down testing. Daily montelukast versus placebo was tested first; if this comparison was significant, intermittent montelukast versus placebo was tested. The significance level was 5%.</p_value_desc>
            <method>Regression, Poisson</method>
            <method_desc>A Poisson regression model containing factors for treatment, age group, and geographic region, and an offset for number of days in study was used.</method_desc>
            <param_type>Rate reduction</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.8</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-19.2</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
            <estimate_desc>Rate reduction = (1 - montelukast-adjusted annual rate/placebo-adjusted annual rate) x 100%</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average of Wheeze and Difficulty Breathing in the 3 Days Prior to Start of an Asthma Attack Within an Asthma Episode</title>
        <description>Each day during an asthma episode, the patient’s legal guardian was asked to rate each of the symptoms of wheeze and difficulty breathing on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 3 days prior to an asthma attack was reported. If a patient had multiple episodes during 1 year, the symptom scores were averaged across all the episodes.</description>
        <time_frame>1 Year</time_frame>
        <population>Only patients who experienced an asthma attack within an episode and did not start their intermittent study medication on the day of the attack could be included. Therefore, a total of 452 patients were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Montelukast</title>
            <description>Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Montelukast</title>
            <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average of Wheeze and Difficulty Breathing in the 3 Days Prior to Start of an Asthma Attack Within an Asthma Episode</title>
          <description>Each day during an asthma episode, the patient’s legal guardian was asked to rate each of the symptoms of wheeze and difficulty breathing on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 3 days prior to an asthma attack was reported. If a patient had multiple episodes during 1 year, the symptom scores were averaged across all the episodes.</description>
          <population>Only patients who experienced an asthma attack within an episode and did not start their intermittent study medication on the day of the attack could be included. Therefore, a total of 452 patients were included in this analysis.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="162"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" lower_limit="1.49" upper_limit="1.88"/>
                    <measurement group_id="O2" value="1.70" lower_limit="1.52" upper_limit="1.89"/>
                    <measurement group_id="O3" value="1.88" lower_limit="1.69" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The secondary hypothesis stated that montelukast (daily regimen, or [intermittent and daily regimens]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.176</p_value>
            <p_value_desc>Multiplicity adjustment across regimens and across primary and secondary endpoints was addressed through step-down testing. Within the 2 endpoints assessing severity, adjustment for multiplicity was performed using Hochberg’s method.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>An ANOVA model containing factors for treatment, age group, and geographical region was used.</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The secondary hypothesis stated that montelukast (daily regimen, or [intermittent and daily regimens]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.202</p_value>
            <p_value_desc>Multiplicity adjustment across regimens and across primary and secondary endpoints was addressed through step-down testing. Within the 2 endpoints assessing severity, adjustment for multiplicity was performed using Hochberg’s method.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>An ANOVA model containing factors for treatment, age group, and geographical region was used.</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average of the Mean Symptom Scores (Wheeze, Difficulty Breathing, Interference With Activity, and Daytime Cough) Assessed Over the 12-day Treatment Period of Asthma Episodes</title>
        <description>Each day during an asthma episode, the patient’s legal guardian was asked to rate each of the symptoms of Wheeze, Difficulty Breathing, Interference with Activity, and Daytime Cough on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 12 days of intermittent treatment for an episode (before the first attack) was reported. If a patient had multiple episodes over 1 year, the symptom scores were averaged across all the episodes.</description>
        <time_frame>1 Year</time_frame>
        <population>Patients with at least one episode culminating in an attack were included; therefore, 1120 patients were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Montelukast</title>
            <description>Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Montelukast</title>
            <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average of the Mean Symptom Scores (Wheeze, Difficulty Breathing, Interference With Activity, and Daytime Cough) Assessed Over the 12-day Treatment Period of Asthma Episodes</title>
          <description>Each day during an asthma episode, the patient’s legal guardian was asked to rate each of the symptoms of Wheeze, Difficulty Breathing, Interference with Activity, and Daytime Cough on a 6-point scale (Scale 0 (best) to 5 (worst)). The average of the individual symptom scores on each of the 12 days of intermittent treatment for an episode (before the first attack) was reported. If a patient had multiple episodes over 1 year, the symptom scores were averaged across all the episodes.</description>
          <population>Patients with at least one episode culminating in an attack were included; therefore, 1120 patients were included in the analysis.</population>
          <units>Units on a Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="387"/>
                <count group_id="O3" value="368"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="1.00" upper_limit="1.16"/>
                    <measurement group_id="O2" value="1.09" lower_limit="1.01" upper_limit="1.17"/>
                    <measurement group_id="O3" value="1.20" lower_limit="1.12" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The secondary hypothesis stated that montelukast (daily regimen, or [intermittent and daily regimens]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <p_value_desc>Multiplicity adjustment across regimens and across primary and secondary endpoints was addressed through step-down testing. Within the family of secondary endpoints, adjustment for multiplicity was performed using Hochberg’s method.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>An ANOVA model containing factors for treatment, age group, and geographical region was used.</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The secondary hypothesis stated that montelukast (daily regimen, or [intermittent and daily regimens]), compared with placebo, results in improvement of respiratory symptoms assessed over 3 days prior to asthma attacks, or assessed over the 12-day treatment period of asthma episodes in pediatric patients aged 6 months to 5 years with episodic asthma and treated over 1 year.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.061</p_value>
            <p_value_desc>Multiplicity adjustment across regimens and across primary and secondary endpoints was addressed through step-down testing. Within the family of secondary endpoints, adjustment for multiplicity was performed using Hochberg’s method.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>An ANOVA model containing factors for treatment, age group, and geographical region was used.</method_desc>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>October 2006 through August 2009</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Daily Montelukast</title>
          <description>Patients were randomized to receive montelukast 4 mg (tablets or oral granules, depending on patient age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
        <group group_id="E2">
          <title>Intermittent Montelukast</title>
          <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of montelukast 4 mg (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Patients were randomized to receive matching-image placebo to montelukast 4 mg (tablets or oral granules, depending on age) once daily at bedtime for 52 weeks plus intermittent 12-day courses of matching-image placebo (tablets or oral granules) once daily at bedtime (a course was initiated as needed for symptoms of imminent respiratory infection or episode of breathing problems) during the 52-week study period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Laryngotracheitis obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Parotid abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="481" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="506" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="486" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="332" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="319" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="585"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="584"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="588"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="585"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

